-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Lowers Price Target to $137

Benzinga·08/06/2026 13:00:59
Listen to the news
Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and lowers the price target from $146 to $137.